MSD has opened a $1bn facility in Durham, in the US state of North Carolina, to increase vaccine manufacturing capacity. The development is part of a broader strategy, with MSD having invested $12bn ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The FDA granted priority review to a supplemental biologics license application ...

The European Commission (EC) has conditionally approved MSD's Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as a single agent for the treatment of adults with von Hippel-Lindau ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved Welireg (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha ...

Lenvima/Welireg combination showed the highest ORR (46.9%) and CBR (59%) among treatment arms in advanced ccRCC patients. Median progression-free survival was longest in the Lenvima/Welireg arm at ...

Welireg was approved in the U.S. in December 2023 for adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-tyrosine kinase inhibitor based on the results from LITESPARK-005.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG ® ...

This marks the first approval for WELIREG in the European Union (EU). WELIREG is now approved in over 30 countries for certain adult patients with previously treated advanced RCC and in more than ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG ® ...